Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GeneSoft Pharmaceuticals Inc.

Division of Oscient Pharmaceuticals Corp.
www.genesoftinc.com

Latest From GeneSoft Pharmaceuticals Inc.

Antibacterials: Biotechs Fill the Big Pharma Void

Big Pharma may have abandoned anti-bacterial research some years ago, but biotechs are filling the void. Their approaches range from improving existing drugs to discovering entirely new targets. Yet although a handful in Europe, including recently floated Basilea and private firm Arrow, has attracted recent investor interest, it hasn't been the anti-bacterials per se that have drawn them in. Basilea benefited from its spin-off status; Arrow from a promising anti-viral project and broad portfolio. Despite growing concerns over bacterial resistance, the field needs success stories to draw investors back for good. Even then, the nature of the diseases and therapies under development mean it's likely to remain the domain of smaller firms.
BioPharmaceutical Europe

Jumpstart to Products

Discovery research is an ever more difficult investment to justify, so companies are placing greater emphasis on mining discoveries that have already been made but whose real value remains unexploited. Big Pharma, in part inhibited by habit and current infrastructure, has not moved aggressively in the new direction-but the jumpstart model now dominates small-company strategies and will increasingly translate into the rest of the industry.
BioPharmaceutical Strategy

In-Licensing: Still a Difficult Model

One way for Pharma to bolster its lagging growth would be to capture some of the value of the compounds it has shelved during development. Start-ups have created technology platforms and systems biology approaches and are in place to reposition such stalled drugs in new indications, or to reformulate marketed compounds to extend the product life cycle. Nonetheless, drug firms largely remain reluctant to part even with compounds they have decided not to develop themselves. Drug makers say the issue is resources, but it is also desire. Until Big Pharma further loosens its grip on its compounds that are stalled in development, in-licensing will remain an opportunistic, case-by-case exercise, and biotechs must accept the fact that access will depend largely on advance insider knowledge of pharma firms' pipelines.
BioPharmaceutical Strategy

Arrow: Focus and Flexibility

In October 2003, infectious diseases start-up Arrow Therapeutics' £21 million funding round from four new international VCs and five existing backers topped the ranks of UK biotech fundraisings. The round shows that investors value a broad pipeline, plus well-connected management able to balance focus with opportunism, more than a product in the clinic or a sexy new technology.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • GeneSoft Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Oscient Pharmaceuticals Corp.
  • Senior Management
  • David B Singer, Chmn. & CEO
    Bruce Cohen, CFO
    Gary Patou, Pres.
    Heinz E Moser, PhD, CTO
  • Contact Info
  • GeneSoft Pharmaceuticals Inc.
    Phone: (650) 742-1800
    7300 Shoreline Ct.
    S. San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register